]>
IRCT20231108059994N1 IRCT 2023-11-25 Mashhad University of Medical Sciences Studying the effect of Rivaroxaban 2.5 mg daily on Arteriovenous hemodialysis graft maintenance and thrombosis Studying the effect of Rivaroxaban 2.5 mg daily on Arteriovenous hemodialysis graft maintenance and thrombosis 2023-03-21 anticipated 78 Complete https://irct.ir/trial/73633 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: simple The envelope method is that the envelopes will be prepared and printed by a member of the research team and random numbers with the help of Randomaize.com and placed inside the envelope. The lid of the envelopes will be closed and its contents will not be visible from the outside. Then, first, the purpose of the study is explained to the person who meets the stated conditions, and if the person wishes, he signs the informed consent form and takes an envelope, then opens it, and based on the contents of the envelope, the person is entered into the intervention or control group, Blinding description: The envelope method is that the envelopes will be prepared and printed by a member of the research team and random numbers with the help of Randomaize.com and placed inside the envelope. The lid of the envelopes will be closed and its contents will not be visible from the outside. Then, first, the purpose of the study is explained to the person who meets the stated conditions, and if the person wishes, he signs the informed consent form and takes an envelope, then opens it, and based on the contents of the envelope, the person is entered into the intervention or control group. 3 Artificial vein thrombosis in dialysis patients. Intervention group: In the intervention group, after implanting an artificial dialysis vessel to the patient, 2.5 daily. mg rivaroxaban. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is I have not decided yet
public Jamal jalili shahri
velayat hospital
Mashhad Iran (Islamic Republic of) 9177899191 051387240 ZangoueiA4001@mums.ac.ir Mashhad University of Medical Sciences scientific Jamal jalili shahri
Mashhad velayat hospital
Mashhad Iran (Islamic Republic of) 9177899191 051387240 ZangoueiA4001@mums.ac.ir Mashhad University of Medical Sciences Iran (Islamic Republic of) Dependence on hemodialysis or the need for hemodialysis in the near future Installing a new artificial vein for dialysis no limit no limit Both Recent major bleeding (within the last 6 months) that is defined as follows: bleeding requiring transfusion, bleeding in a high-risk area (retroperitoneal or intracranial), bleeding that caused a decrease in body volume or hospitalization, or bleeding that caused Hg drop is more than 2 gr/dl. Inability to take oral medication Anticoagulant use for another reason Life expectancy of less than two months or waiting for recovery of renal failureOpen in T82.867A Thrombosis of cardiac prosthetic devices, implants and grafts, initial encounter Prevention Intervention group: In the intervention group, after implanting an artificial dialysis vessel to the patient, 2.5 daily. mg rivaroxaban Thrombosis rate of artificial vein in one, three and six months after implantation of artificial dialysis vessel. Timepoint: in one, three and six months after implantation of artificial dialysis vessel. Method of measurement: Occurrence of thrombosis in an artificial vessel. Mashhad University of Medical Sciences Approved 2023-06-15 Ethics Committee of Mashhad Medical Sciences shahid kalantari Blvd. Mashhad University of Medical Sciences mashhad Razavi Khorasan Iran (Islamic Republic of)